225,000 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Integral Health Asset Management LLC

Integral Health Asset Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 225,000 shares of the biotechnology company’s stock, valued at approximately $7,760,000. Integral Health Asset Management LLC owned 0.16% of Arrowhead Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ARWR. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $29,000. Virtus Advisers LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth about $34,000. Salomon & Ludwin LLC bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at about $34,000. Federated Hermes Inc. purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth about $52,000. Finally, Smartleaf Asset Management LLC raised its position in Arrowhead Pharmaceuticals by 2,186.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,618 shares during the period. Institutional investors own 62.61% of the company’s stock.

Insiders Place Their Bets

In other news, insider James C. Hamilton sold 10,000 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $64.19, for a total transaction of $641,900.00. Following the transaction, the insider owned 236,958 shares of the company’s stock, valued at approximately $15,210,334.02. This represents a 4.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Adeoye Y. Olukotun sold 10,000 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the transaction, the director owned 33,600 shares in the company, valued at approximately $2,273,376. This represents a 22.94% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 495,836 shares of company stock worth $32,759,810. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $55.05 on Friday. The company has a 50 day moving average price of $64.47 and a 200-day moving average price of $51.15. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $76.76. The company has a market capitalization of $7.71 billion, a PE ratio of 35.98 and a beta of 1.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). The firm had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm’s revenue for the quarter was up 10461.3% compared to the same quarter last year. During the same period last year, the company earned ($1.39) EPS. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Ratings Changes

ARWR has been the subject of several analyst reports. Royal Bank Of Canada raised their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. The Goldman Sachs Group increased their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. B. Riley Financial raised their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Piper Sandler restated an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Finally, Morgan Stanley upped their price objective on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $81.67.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.